Skip to main content
Sonoma Pharmaceuticals, Inc. logo

Sonoma Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · SNOA ISIN · US83558L2043 US Manufacturing
Open in API
Filings indexed 951 across all filing types
Latest filing 2012-11-05 Regulatory Filings
Country US United States of America
Listing US SNOA

About Sonoma Pharmaceuticals, Inc.

https://sonomapharma.com/

Sonoma Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and commercializes products based on its patented Microcyn® Technology, a stabilized hypochlorous acid (HOCl) platform. With over 20 years of experience, the company produces a range of prescription and over-the-counter solutions for advanced wound care, dermatology, animal health, and eye care. Its products are designed to manage various conditions by promoting healing and reducing the risk of infection. The portfolio serves healthcare professionals in settings like hospitals and nursing homes, as well as consumers for at-home use.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text mentions a press release about compliance with NASDAQ listing rules and includes forward-looking statements. It does not contain detailed financial statements or comprehensive financial analysis. The document length is 3467 characters, which is relatively short and primarily serves as an announcement rather than a full report. Therefore, it fits the category of a Regulatory Filing (RNS), which is a general category for miscellaneous filings that do not fit other specific categories.
2012-11-05 English
Capital/Financing Update 2012
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes entering into material definitive agreements related to debt restructuring and issuance of common stock to reduce liabilities. It also references amendments to loan agreements and warrants, and includes exhibits such as stock purchase agreements and letter agreements. There is a mention of a press release announcing quarterly financial results, but the 8-K itself is focused on the financing transactions and amendments. The document is not a full financial report like an Annual Report (10-K) or Interim Report (IR), nor is it a simple announcement of a report publication. It is primarily an update on capital and financing activities, including stock issuance and debt restructuring. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence in this classification.
2012-11-01 English
Regulatory Filings 2012
Regulatory Filings
2012-10-24 English
Regulatory Filings 2012
Regulatory Filings
2012-10-18 English
FORM 4
Director's Dealing
2012-10-02 English
FORM 4
Director's Dealing
2012-10-02 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.